Coenfy (xanomeline–trospium), approved by the U.S. Food and Drug Administration in 2024, represents the first antipsychotic with a non-dopaminergic mechanism of action and expands current treatment options by introducing a novel cholinergic therapeutic strategy.
Gabriela Majchrowicz, Mikołaj Jońca, Natasza Kurys et al.· International Journal of Inn...· 0 citations
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interpl...
Mikołaj Jońca, Gabriela Majchrowicz, Natasza Kurys et al.· International Journal of Inn...· 0 citations
Underdiagnosis of ADHD in women remains a significant clinical and public health issue, and greater awareness of sex-specific symptom presentation and improved diagnostic strategies are essential to prevent long-term psychosocial consequences and improve quality of life in affected women.
N. Samp, P. Trzepizur, Kamila Zera et al.· Quality in Sport· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.